Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy

Journal of the Medical Association of Thailand

Volumn 83, Issue 10, 2000, Pages 1187-1195

  Ratanatharathorn, V ^a   Sirachainan, E ^a   Jirajarus, M ^a   Sirilerttrakul, S ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Advanced Colorectal Cancer (CRC); Irinotecan

Indexed keywords

FLUOROURACIL; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; METASTASIS; MULTIDRUG RESISTANCE; NEUTROPENIA; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034506089     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report
2. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
3. Surgical treatment of liver metastases in patients with colorectal cancer
4. Chemotherapy for colorectal cancer
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
6. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial
7. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
8. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
9. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
10. Topoisomerase I inhibitors: Topotecan and irinotecan
11. Arrest of replication forks by drug-stabilise topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
12. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
13. Intracellular roles of SN-38, a metabolite of camptothecin derivative CPT-11, in the antitumor effect of CPT-11
14. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts
15. Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues
16. CPT-11 (irinotecan) in the treatment of colorectal cancer
17. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
18. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
19. Phase I and pharmacologic studies of the camptothecin analog Irinotecan administered every three weeks in cancer patients
20. Reporting results of cancer treatment
21. Non-parametric estimation from incomplete observations
22. Tumor response and stabilization rates are worthwhile surrogate efficacy endpoints in metastatic colorectal cancer (CRC)Analysis of data in 455 5-FU resistant patients treated with CPT-11
23. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer
24. Phase II study of Irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
25. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer
26. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU
27. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer
28. Long-term survivors in metastatic non-small-cell lung cancer: An ECOG study
29. The role of chemotherapy in the treatment of multiple myeloma
30. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
31. Paclitaxel in breast cancer: Early and advanced stages of the disease
32. The role of intestinal barrier failure and bacterial translocation in the development of systemic infection and multiple organ failure
33. Bacterial translocation from the gastrointestinal tract
34. Irinotecan and 5-fluorouracil in colorectal cancer: Time for a pause?